SPRAVATO®, the only FDA-approved nasal spray for adults with treatment-resistant depression, reduces depression symptoms when two or more oral antidepressants haven't worked. SPRAVATO® can be taken with or without an oral antidepressant.

Jan 27, 2025 · The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for...

Jan 22, 2025 · The U.S. Food and Drug Administration has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with treatment ...

The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried...

Jan 27, 2025 · The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

Aug 23, 2023 · Spravato (esketamine) nasal spray is used for treatment-resistant depression and major depressive disorder (MDD) with acute suicidal ideation or behavior. Includes Spravato side effects, interactions and indications.

Jan 28, 2025 · The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

But it wasn’t until recently that esketamine, a more potent version of ketamine, earned FDA approval specifically for use as a nasal spray for those with treatment-resistant depression. Esketamine is derived from part of the ketamine molecule,” says …

A recent Phase 4 clinical trial 1 found that, four weeks after starting Spravato, 22.5% of participants with major depressive disorder who took the nasal spray alongside an oral antidepressant achieved remission from depression symptoms, compared to 7.6% of participants achieving relief on an oral antidepressant and placebo spray.

Aug 14, 2024 · Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not...